IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Clinical trials for IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA explained in plain language.
Never miss a new study
Get alerted when new IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA trials appear
Sign up with your email to follow new studies for IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug could reduce need for plasma exchange in rare blood disorder
Disease control CompletedThis study tested a drug called TAK-755 in 29 adults with a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP). The goal was to see if TAK-755, along with standard immune-suppressing drugs, could control the disease with little or no pl…
Matched conditions: IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Breakthrough drug combo may replace plasma exchange for rare blood disease
Disease control CompletedThis study tested whether a drug called caplacizumab, combined with immune-suppressing medicines, could treat a rare blood clotting disorder called immune-mediated thrombotic thrombocytopenic purpura (iTTP) without the usual plasma exchange procedure. Fifty-one adults aged 18 to …
Matched conditions: IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC